FOXO4 – 10 Vials (CAS: 2460055-10-9)

$610.00

FOXO4-DRI is a synthetic senolytic peptide designed to disrupt the FOXO4–p53 protein interaction, selectively inducing apoptosis in senescent cells while sparing healthy cells. This high-purity lyophilized powder is a valuable research tool for investigating cellular senescence, age-related tissue dysfunction, and senolytic therapeutic strategies. Supplied for laboratory research use only.

Description

FOXO4-DRI (FOXO4-D-Retro-Inverso) is a synthetic peptide composed entirely of D-amino acids in a retro-inverso configuration, corresponding to the p53-binding domain of the forkhead box protein O4 (FOXO4). This design confers resistance to enzymatic degradation and enhanced cellular uptake, typically achieved through fusion with a cell-penetrating peptide (CPP) sequence such as HIV-TAT.

The peptide functions as a specific inhibitor of the FOXO4–p53 interaction. In senescent cells, FOXO4 is upregulated and sequesters p53 in nuclear bodies, preventing p53 from initiating apoptosis. FOXO4-DRI competes with FOXO4 for p53 binding, displacing p53 from the nucleus and allowing it to translocate to mitochondria, where it triggers cytochrome c release and caspase-mediated apoptosis.

This product is supplied as a sterile lyophilized powder and is intended strictly for research purposes only. It is NOT for human or veterinary consumption.

 

Key Research Focus

FOXO4-DRI has been investigated in preclinical research exploring its roles in:

  • Selective Senescent Cell Clearance: FOXO4-DRI selectively kills senescent cells without affecting non-senescent cells across a broad concentration window. In human chondrocytes expanded in vitro, FOXO4-DRI treatment removed more than half of late-passage (PDL9) cells while not significantly affecting early-passage (PDL3) cells.
  • Chemotoxicity and Aging Models: In doxorubicin-treated mice, FOXO4-DRI reduced senescent cell burden and neutralized the drug’s toxic effects, including restoring body weight and reducing liver damage markers. In fast-aging Xpd^TTD/TTD and aged mice, the peptide restored juvenile traits including greater hair density, increased voluntary physical activity, and protected against progressive kidney function loss.
  • Pulmonary Fibrosis: In bleomycin-induced pulmonary fibrosis models, FOXO4-DRI treatment reduced collagen deposition and extracellular matrix protein content. The peptide reset intranuclear p53 distribution and decreased fibroblast activation markers.
  • Keloid and Fibrotic Skin Disorders: FOXO4-DRI selectively induced apoptosis in keloid senescent fibroblasts by promoting nuclear exclusion of phosphorylated p53 (p53-pS15). Non-senescent fibroblasts were unaffected.
  • Vascular Aging: In aged and progeroid mice, FOXO4-DRI injection suppressed aortic aging and improved aortic function. In senescent endothelial cells, the peptide facilitated p53 nuclear exclusion and activated the p53/BCL-2/Caspase-3 pathway.
  • Neuropathic Pain: In a spared nerve injury (SNI) model, intrathecal FOXO4-DRI administration reduced mechanical allodynia and decreased senescence pathway and SASP effector gene expression in the spinal cord.
  • Spermatogenesis in Aged Mice: FOXO4-DRI improved spermatogenesis by reducing senescence-associated secretory phenotype (SASP) secretion from Leydig cells.

 

Molecular Mechanism (Recent Structural Insights)

A 2025 study in Nature Communications provided detailed structural characterization of FOXO4-DRI’s mechanism. Solution NMR models revealed that the disordered FOXO4-DRI binds to the disordered p53 transactivation domain 2 (p53TAD2), forming a transiently folded complex. Both the FOXO4-derived region and the cationic cell-permeability peptide contribute to the interaction. Notably, phosphorylation of p53TAD2 at Ser46 and Thr55 enhances binding affinity for both FOXO4 and FOXO4-DRI, suggesting a mechanism for preferential targeting of senescent cells where p53 is phosphorylated.

 

Product Specifications

  • Form: Lyophilized Powder (Sterile)
  • Purity: ≥95% (HPLC Verified)
  • Composition: All-D-amino acid retro-inverso peptide corresponding to FOXO4 p53-binding domain
  • Sequence: D-retro-inverso form of FOXO4 forkhead domain interaction region, typically fused to a CPP (e.g., HIV-TAT)
  • Storage: Store at -20°C (freezer) for long-term stability. Protect from light.
  • Solubility: Soluble in sterile water or buffer for laboratory use.
  • Disclaimer: This product is a chemical reagent for research purposes only. It is NOT for human or animal consumption, diagnostic, or therapeutic use.

 

Why Choose FOXO4-DRI?

FOXO4-DRI represents a mechanistically distinct approach to senolytic research, targeting a specific protein-protein interaction (FOXO4–p53) rather than broadly inhibiting anti-apoptotic proteins like BCL-2. Its design as a D-retro-inverso peptide confers enhanced stability and cellular uptake. Preclinical studies have demonstrated selective senescent cell clearance across multiple cell types and tissue models, with a favorable tolerance profile in mice. The availability of detailed structural insights into its binding mechanism provides a rational foundation for experimental design and data interpretation.

Additional information

Grams

10mg

Disclaimer: Supplied strictly as a high-purity chemical reagent for laboratory research and development use only. Not for human or animal consumption.

Our Products